Search

Your search keyword '"Bodova, Ivana"' showing total 8 results
Start Over Author "Bodova, Ivana" Search Limiters Peer Reviewed
8 results on '"Bodova, Ivana"'

1. Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP

Author

Wachowiak, Jacek, Galimard, Jacques-Emmanuel, Dalissier, Arnaud, Rihani, Rawad, AlSaedi, Hawazen, Wynn, Robert F., Dalle, Jean-Hugues, Peffault de Latour, Régis, Sedlacek, Petr, Balduzzi, Adriana, Schroeder, Thomas, Bodova, Ivana, Gonzalez Vicent, Marta, Gruhn, Bernd, Hamladji, Rose-Marie, Krivan, Gergely, Patrick, Katharine, Sobkowiak-Sobierajska, Agnieszka, Stepensky, Polina, Unal, Ali, Amrolia, Persis, Perez Martinez, Antonio, Rialland, Fanny, Aljurf, Mahmoud, Isgro, Antonella, Toren, Amos, Bierings, Marc, Corbacioglu, Selim, and Kałwak, Krzysztof

Published
2024
Full Text
View/download PDF

2. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study

Author

Sharma, Akshay, Galimard, Jacques-Emmanuel, Pryce, Angharad, Bhoopalan, Senthil Velan, Dalissier, Arnaud, Dalle, Jean-Hugues, Locatelli, Franco, Jubert, Charlotte, Mirci-Danicar, Oana, Kitra-Roussou, Vassiliki, Bertrand, Yves, Fagioli, Franca, Rialland, Fanny, Biffi, Alessandra, Wynn, Robert F., Michel, Gérard, Tambaro, Francesco Paolo, Al-Ahmari, Ali, Tbakhi, Abdelghani, Furness, Caroline L., Diaz, Miguel Angel, Sedlacek, Petr, Bodova, Ivana, Faraci, Maura, Rao, Kanchan, Kleinschmidt, Katharina, Petit, Arnaud, Gibson, Brenda, Bhatt, Neel S., Kalwak, Krzysztof, and Corbacioglu, Selim

Published
2024
Full Text
View/download PDF

3. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Author

Aiuti, Alessandro, Maschan, Alexei, Aljurf, Mahmoud, Gedde-Dahl, Tobias, Gurman, Gunhan, Bordon, Victoria, Kriván, Gergely, Locatelli, Franco, Porta, Fulvio, Valcárcel, David, Beguin, Yves, Faraci, Maura, Kröger, Nicolaus, Kulagin, Aleksandr, Shaw, Peter J., Veelken, Joan Hendrik, Diaz de Heredia, Cristina, Fagioli, Franca, Felber, Matthias, Gruhn, Bernd, Holter, Wolfgang, Rössig, Claudia, Sedlacek, Petr, Apperley, Jane, Ayas, Mouhab, Bodova, Ivana, Choi, Goda, Cornelissen, J.J., Sirvent, Anne, Khan, Anjum, Kupesiz, Alphan, Lenhoff, Stig, Ozdogu, Hakan, von der Weid, Nicolas, Rovira, Montserrat, Schots, Rik, Vinh, Donald C., Albert, Michael H., Sirait, Tiarlan, Eikema, Dirk-Jan, Bakunina, Katerina, Wehr, Claudia, Suarez, Felipe, Fox, Maria Laura, Mahlaoui, Nizar, Gennery, Andrew R., Lankester, Arjan C., Beier, Rita, Bernardo, Maria Ester, Bigley, Venetia, Lindemans, Caroline A., Burns, Siobhan O., Carpenter, Ben, Dybko, Jaroslaw, Güngör, Tayfun, Hauck, Fabian, Lum, Su Han, Balashov, Dmitry, Meisel, Roland, Moshous, Despina, Schulz, Ansgar, Speckmann, Carsten, Slatter, Mary A., Strahm, Brigitte, Uckan-Cetinkaya, Duygu, Meyts, Isabelle, Vallée, Tanja C., Wynn, Robert, Neven, Bénédicte, and Morris, Emma C.

Published
2022
Full Text
View/download PDF

4. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis

Author

Albert, Michael H., Slatter, Mary A., Gennery, Andrew R., Güngör, Tayfun, Bakunina, Katerina, Markovitch, Benyamin, Hazelaar, Sheree, Sirait, Tiarlan, Courteille, Virginie, Aiuti, Alessandro, Aleinikova, Olga V., Balashov, Dmitry, Bernardo, Maria Ester, Bodova, Ivana, Bruno, Benedicte, Cavazzana, Marina, Chiesa, Robert, Fischer, Alain, Hauck, Fabian, Ifversen, Marianne, Kałwak, Krzysztof, Klein, Christoph, Kulagin, Alexander, Kupesiz, Alphan, Kuskonmaz, Baris, Lindemans, Caroline A., Locatelli, Franco, Lum, Su Han, Maschan, Alexey, Meisel, Roland, Moshous, Despina, Porta, Fulvio, Sauer, Martin G., Sedlacek, Petr, Schulz, Ansgar, Suarez, Felipe, Vallée, Tanja C., Winiarski, Jacek H., Zecca, Marco, Neven, Bénédicte, Veys, Paul, and Lankester, Arjan C.

Published
2022
Full Text
View/download PDF

5. Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia.

Author

Yoshimi, Ayami, Noellke, Peter, Starý, Jan, Kállay, Krisztián, Smith, Owen, Locatelli, Franco, Buechner, Jochen, Bodova, Ivana, Sevilla, Julian, Schmugge, Markus, Bierings, Marc, Masmas, Tania, Dworzak, Michael, Labarque, Veerle, Pawelec, Katarzyna, Jahnukainen, Kirsi, Polychronopoulou, Sophia, Kjollerstrom, Paula, Kavcic, Marko, and Erlacher, Miriam

Published
2024
Full Text
View/download PDF

6. First case of invasive Magnusiomyces capitatus infection in Slovakia.

Author

Tanuskova, Dominika, Horakova, Julia, Svec, Peter, Bodova, Ivana, Lengerova, Martina, Bezdicek, Matej, Poczova, Miroslava, Koppl, Jozef, and Kolenova, Alexandra

Abstract

Magnusiomyces capitatus (previously known as Geotrichum capitatum or Blastoschizomyces capitatus or Trichosporon capitatum ) is a rare cause of fungal infection in immunocompromised patients. Most of these cases (87%) have been reported from the Mediterranean region, as it is extremely rare to recognize it in other regions. Here we report a first case of disseminated M. capitatus infection in Slovakia. The patient – 19 year old woman with myelodysplastic syndrome was diagnosed with M. capitatus fungemia after allogeneic stem cell transplantation. The infection occurred despite antifungal prophylaxis with micafungin, which was in vitro sensitive to the yeast. The treatment according to minimal inhibitory concentrations (micafungin, voriconazol) and granulocyte transfusions were administered. M. capitatus was cleared out from the bloodstream. However, patient died of multiple organ failure. Autopsy showed multiple lesions in organs, but did not prove presence of yeast by histopathology. M. capitatus was confirmed by polymerase chain reaction from all tested organs: heart, brain, lungs, spleen, liver and kidneys. We present the post mortem pictures showing the yeast lesions in affected organs. 2012 Elsevier Ltd. All rights reserved. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

7. Allogeneic stem cell transplantation for acquired pure red cell aplasia.

Author

Halkes, Constantijn, Wreede, Liesbeth C, Knol, Cora, Simand, Célestine, Aljurf, Mahmoud, Tbakhi, Abdelghani, Vazquez, Lourdes, Bloor, Adrian, Wagner‐Drouet, Eva, Vural, Filiz, Bodova, Ivana, Isaksson, Cecilia, Diaz, Miguel Ángel, Gruhn, Bernd, Snowden, John, Arat, Mutlu, Bazarbachi, Ali, Spilleboudt, Chloé, Kulagin, Alexander, and Marsh, Judith CW

Published
2019
Full Text
View/download PDF

8. Busulfan/Fludarabine- or Treosulfan/Fludarabine-Based Conditioning Regimen for Patients with Wiskott-Aldrich Syndrome – an EBMT Inborn Errors Working Party and Scetide Study.

Author

Albert, Michael H., Slatter, Mary, Gennery, Andrew, Gungor, Tayfun, Blok, Henric-Jan, Hazelaar, Sheree, Wang, Junfeng, Courteille, Virginie, Mahlaoui, Nizar, Bernado, Maria Ester, Bodova, Ivana, Bruno, Bénédicte, Bykova, Tatiana, Chiesa, Robert, Fischer, Alain, Formankova, Renata, Kalwak, Krzysztof, Klein, Christoph, Kozlovskaya, Svetlana, and Kupesiz, Alphan

Subjects
*BUSULFAN, *WISKOTT-Aldrich syndrome, *INBORN errors of metabolism, *GENETIC disorder treatment, *HEMATOPOIETIC stem cell transplantation
Abstract

Introduction Excellent survival rates have been reported after allogeneic haematopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome (WAS) patients. Recipient age >5 years in MUD HSCT as well as MMFD as donor were negative predictors for outcome. However, the vast majority of HSCTs in previously published studies were performed with (oral) busulfan/cyclophosphamide-based conditioning and in the early 2000 years or before. Objectives To compare OS and EFS after HSCT with either busulfan/fludarabine (BuFlu) ± thiotepa (TT) or treosulfan/fludarabine (TreoFlu) ± TT as recommended for primary immunodeficiencies since 2005 by the inborn errors working party (IEWP) of EBMT and ESID. Methods We performed a retrospective analysis via the EBMT and SCETIDE registries of WAS patients transplanted between 20006 and 2016 with these two regimens. At the time of this interim analysis, 174 patients were included, 92 (53%) with BuFlu±TT and 82 (47%) with TreoFlu±TT conditioning, with a median age of 1.6 years (0.2-30) at HSCT and a median follow-up of 32.9 months (1.5-128.9). Donors were MSD in 30, other MRD in 5, MUD (9/10 or 10/10) in 105, MMUD (<9/10) in 9 and MMFD in 25 (18 with ex-vivo T-cell depletion). Stem cell source was bone marrow in 93, peripheral blood in 62 and cord blood in 18. Results Two year overall survival (OS) of the entire cohort was 88.6% (95% c.i. 83.5%-93.6%). There was no significant difference in OS between BuFlu±TT or TreoFlu±TT conditioning (2-year OS 88.1% vs. 89.5%; p=0.7). Patients aged >5 years had a worse OS as compared to those 5 years or younger at HSCT (74.9% vs. 90.8%; p=0.005). The type of donor had no influence on OS: 96.4% for MSD/MFD, 86.8% for MUD/MMUD and 87.7% for MMFD (p=0.4). The rate of complete (≥90%) donor chimerism at last follow-up or before a secondary procedure (if a patient had one) was 41/42 (98%) in the BuFlu±TT group and 21/35 (60%) in the TreoFlu±TT group (p=0.0001). Twenty-six patients required a second procedure: stem cell boost in 4, donor lymphocyte infusion in 9, 2nd HSCT in 15 and splenectomy in 1. The 2-year cumulative incidence (CI) of second procedures was higher at 33.9% in the TreoFlu±TT versus 12.8% in the BuFlu±TT group (p=0.017), and 2-year EFS (events: second procedure or death) was 61.4% in the TreoFlu±TT and 75.0% in the BuFlu±TT group (p=0.2). Grade II-IV acute GVHD had the same incidence in both groups (24.4% vs. 26.3%; p=0.849) and chronic GVHD of any grade was borderline more frequent in the TreoFlu±TT group (17.2% vs 6.7%; p=0.054). Conclusion HSCT with either BuFlu±TT or TreoFlu±TT conditioning reliably cures almost 90% of patients with WAS regardless of donor type. Age >5 years at HSCT remains a negative risk factor. More patients were mixed chimeras and required second procedures after TreoFlu±TT than after BuFlu±TT conditioning. These data confirm the feasibility and efficacy of the regimens currently recommended by the IEWP. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results